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Bassem RefaatAbstract
Embryo implantation is a major prerequisite for the successful establishment of pregnancy. Ectopic implantation
outside the intrauterine cavity and the development of ectopic pregnancy (EP) is a major cause of maternal morbidity
and occasionally mortality during the first trimester. EP may be induced by failure of tubal transport and/or increased
tubal receptivity. Activins, their type II receptors and follistatin have been localised in the human endometrial and tubal
epithelium and they are major regulators of endometrial and tubal physiology during the menstrual cycle. Pathological
expression of activins and their binding protein, follistatin, was observed in tissue and serum samples collected from
EP. Several studies with different designs investigated the diagnostic value of a single measurement of serum activin-A
in the differentiation between normal intrauterine and failing early pregnancy and the results are controversial.
Nevertheless, the diagnostic value of activins in EP, including the other activin isoforms (activin-B and –AB) and follistatin,
merits further research. This review appraises the data to date researching the role of activins in the establishment of
normal pregnancy and, pathogenesis and diagnosis of tubal EP.
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The complex process of implantation and trophoblast
invasion is crucial for the successful establishment of
pregnancy [1-3]. Normally an embryo implants in the
endometrium during the implantation window and uter-
ine receptivity for implantation is maximal during this
period [3]. Endometrial receptivity involves the expres-
sion of molecular factors that govern the feto-maternal
dialogue and initiate decidualisation of the endometrial
stroma [1,2]. Candidate molecules, including cytokines
and growth factors, are secreted by endometrial and
tubal epithelial cells and have been described as major
regulators of blastocyst implantation [4].
Ectopic pregnancy (EP) is a form of abnormal preg-
nancy in which the fertilised ovum implants outside the
intrauterine cavity and the ampullary region of the fallo-
pian tube is the most common site of implantation [5,6].
EP represents 1-2% of all pregnancies in developed
countries and haemorrhage from an EP due to tubal
rupture remains the most common cause of maternalCorrespondence: bassem.refaat@yahoo.co.uk
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unless otherwise stated.mortality in the first trimester of pregnancy in those
countries [7-9].
Little is known about the reasons why embryos in
some pregnancies implant within the fallopian tube
whilst most implant eutopically within the endometrium
of the uterus [4,10]. Ectopic implantation has long been
attributed to failure of the tubal transport mechanism.
Either/or the rhythmic smooth muscle contraction and
ciliary beat activity are believed to fail thereby leading
to an EP. An alternative explanation for EP would be an
increase in tubal epithelial receptivity as a result of
delay in the tubal transport and impaired endometrial
receptivity with ectopic implantation occurring follow-
ing failure of the normal biological interactions between
endometrium, fallopian tube and embryo [4,10].
Quantitative measurement of human chorionic gonado-
tropin (hCG) in combination with transvaginal ultrasound
is the currently accepted paradigm for clinical diagnosis
and management of EP, with hCG monitoring being used
to follow patients until complete resolution of the EP
[7,8,11,12]. EP can be treated surgically by laparotomy or
laparoscopy, medically by methotrexate (MTX) injection
and occasionally by observation alone [8]. MTX is the
most cost effective and has similar effect as laparoscopicis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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EP. However, it requires early detection of EP as it is only
suitable in haemodynamically stable patients, with min-
imal or no symptoms, initial serum hCG ≤3000 IU/L, EP
size <4 cm and absence of foetal cardiac activity [13-15].
It is believed that almost 50% of EP cases are initially
misdiagnosed despite the use of high-resolution transvagi-
nal sonography and sensitive assays for β-hCG [7,8,16,17].
The delay in the diagnosis of EP eliminates the option of
conservative management, could lead to tubal rupture,
maternal morbidity and/or mortality. Hence, there is a
compelling need to develop new markers and algorithms
that provide a more sensitive and specific tool for the
diagnosis of EP [11,18,19].
Activins and their binding protein, follistatin, are
abundantly expressed in the female reproductive tract
and they have recently been proposed as potential sensi-
tive and specific markers for the diagnosis of ectopic
pregnancy by several research groups [20-22]. The current
review summarises the physiological actions of activins
and follistatin in the endometrium, fallopian tube, embryo
implantation and their clinical value in the diagnosis of
normal and abnormal early pregnancies.
Methods
‘Medline’ and ‘EMBASE’ were searched using the
terms ‘endometrium’, ‘fallopian tube’, ‘implantation’,
‘early pregnancy’, ‘ectopic pregnancy’, ‘tubal preg-
nancy’, ‘early pregnancy loss’, ‘failing early pregnancy’,
‘receptivity’, ‘decidualization’, ‘implantation failure’ and
‘trophoblast’ in combination with ‘activin’ or ‘follista-








Figure 1 Structure of activin mature dimer proteins. The β-subunits are
signal peptide and pro-region, both of which are cleaved to form the mat
by disulphide bridges.Publications in the past 6 years were mostly selected,
but commonly referenced and important older pub-
lications were not excluded. The reference lists of
articles identified by this search strategy were also
searched and those judged as relevant were included.
For a study to be included, it needed to be primarily
focused on the expression of activins and their related
molecules by the endometrial and tubal tissues, their roles
in the establishment of normal and abnormal pregnancies
and their serological diagnostic values in failing early preg-
nancies. Studies that were solely epidemiological in nature
were excluded.
Structure, cell signalling and regulation of activins
bioactivities
Activins are members of the transforming growth factor-
β family and they were originally isolated from porcine
follicular fluid in 1986. They were termed after their
stimulatory effect on the secretion of follicle stimulating
hormone from the pituitary gland. Activins were later
found to be secreted by all organs of the female repro-
ductive system where they function as paracrine and
autocrine factors to regulate a variety of reproductive
functions [21,23,24].
Activins are homodimers or heterodimers of two β-
subunits (βA and βB), and the different dimerization of
subunits by a disulphide bond gives rise to three mature
proteins named activin-A (βA-βA), activin-B (βB-βB) and
activin-AB (βA-βB) (Figure 1) [23]. The human activin
βA-subunit and βB-subunit genes are located on chromo-
some7 locus7p14-p15 and chromosome 2qcen-q13, re-






produced as larger precursor proteins, prepro-βA and -βB, that include a
ure β-subunit. Activins are dimers consisting of two β-subunits joined
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sequence homology and both of them lack recognized
glycosylation sites [26].
Activins mediate their actions by binding to a complex
of transmembrane serine and threonine kinase receptors.
These activin receptors are classified into type I and type
II receptor groups, comprising the activin type IIA and
type IIB receptors (ActRIIA and ActRIIB) [23]. Activins
can bind their individual receptor type II when expressed
alone, but fail to bind to type I receptor in the absence of
type II receptor [27]. However, both type I and II recep-
tors are necessary to generate a high-affinity complex with
the ligand, as well as for signalling (Figure 2) [28].
The coordinated synthesis of follistatin with activin is
the main regulator of the local bioactivity of activin since
binding of activin to follistatin is almost irreversible [23].
The activin-follistatin complex generally consists of one
activin dimer and two follistatin molecules [29]. In gen-
eral, activin-A, −AB, and -B bind to follistatin with simi-
lar affinity (Figure 3) [30].
Both activin subunits, activin type II receptors and follis-
tatin were previously localised within the human fallopian
tube [23,31], endometrium [32-34] and placental [35]
tissues suggesting a role for these proteins in the regula-
tion the physiological functions of these tissues. Therefore
these proteins have been proposed as potential sensitive
and specific markers to monitor the progress and out-
come of pregnancy [36,37].Roles of activins in normal early pregnancy events
Activins are potential factors for maternal–embryo inter-
actions, due to their roles in regulating cell proliferation,
differentiation and apoptosis, and their abundant expres-
sion and actions in remodelling tissues, embryogenesis






Figure 2 The signalling mechanism of activin. (1) Activin dimer binds to
the type I receptors. (4) The activin type I receptors transduce the activin signaActivins in tubal physiology
Fertilisation and pre-implantation embryo development
occur in the fallopian tube following ovulation and, the
tubal epithelium is biologically active providing secretions
to support these processes [23,38]. The fertilised ovum
travels through the fallopian tube under the control of
tubal ciliary beat frequency and tubal smooth muscle
contraction to reach to the intrauterine cavity for implant-
ation within 48–72 h after fertilisation [39]. Impaired tubal
transportation and secretory functions can occur after ex-
ternal or internal inflammation, leading to tubal damage,
ectopic pregnancy and infertility [40].
Early reports on the expression of activin subunits in
the fallopian tube were generated from different animal
species. Originally, only βA-subunit expression was de-
tected at the protein and gene levels in rat [41] and bovine
[42] tubal tissues. Follistatin expression was not included
in either study [41,42]. Consistently, the expression of acti-
vins and follistatin by the human endosalpinx in pre- and
postmenopausal women has been demonstrated [23,31].
In all tissues studied, the βA- and βB-subunits were co-
expressed with their type II receptors and binding protein,
suggesting that the activin dimer has a local paracrine or
autocrine role within the tube [23,31].
Another study has later reported that the expression
of both activin subunits mRNA and protein vary in a
cycle-dependent manner in the oviduct of non-pregnant
cycling mice [34]. The predominant source of activin β-
subunits during the estrous cycle and pre-implantation
phase were the epithelial cells lining the oviduct and
endometrium [34]. A similar pattern of expression by
the tubal epithelium during the menstrual cycle has also
been reported in human fallopian tube and the expres-
sion of activin βA- and βB-subunits, activin type II re-
ceptors, and follistatin was highest in the luteal phase at





the activin type II receptors, (2) which in turn recruit and (3) phosphorylate
l to the nucleus.








Figure 3 The regulation of activin signalling by follistatin. The activin-follistatin complex generally consists of one activin dimer and two follistatin
molecules, which bind activin with high affinity and prevents binding of activin to its receptors.
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physiology and early embryonic development [38].
The mouse and human oocyte is capable of receiving
an activin signal produced by surrounding cumulus cells,
but not of transmitting one [43]. This is further sup-
ported by the findings that early mouse and human em-
bryos, from the four-cell stage to the morula stage, are
unable to synthesise activins as no mRNA for these pro-
teins has been identified at these stages of development
[41,44]. However, the expression of these molecules in-
creased noticeably at the blastocyst stage, suggesting that
the expression of the βA-subunit, activin type I receptor
and follistatin is dependent on embryonic developmental
stage and activation of the embryonic genome in mouse
and human [44]. Therefore it has been postulated that
activins, which bind to the activin type I and type II re-
ceptors on the oocyte and preimplantation embryo, may
be derived from the surrounding tissue such as the tubal
epithelium [34,44].
At the present time, there is no evidence about a role
for activins in the regulation of tubal ciliary beat fre-
quency and smooth muscle contraction [6,38]. However,
several studies have shown that activin-A induces the
production of nitric oxide, a potent inhibitor of tubal
peristalsis, in a concentration-dependent manner in a
variety of tissues and cells [45-47]. Furthermore, it has
shown that activin-A decreased the expression of oxyto-
cin and HoxA-10 mRNA by human myometrial cells
in vitro and it decreased oxytocin and thromboxaneA2
induced accumulation of intracellular Ca+2 [48]. There-
fore, activin-A could have a relaxing effect on human
fallopian tube smooth muscle by stimulating the produc-
tion of nitric oxide and/or by decreasing accumulation
of intracellular Ca+2 [6].Activins in endometrial physiology
The endometrium performs morphological and secretory
adjustments during the menstrual cycle to form a recep-
tive soil for the arriving blastocyst in the late luteal phase
[1,2,4]. These alterations include the appearance of
pinopodes in the epithelial layer, decidualization of the
endometrial stroma and vascular proliferation, which are
absolute requirements for successful implantation and es-
tablishment of communications with the embryo [1,2,4].
These modifications occur under the regulation of ovarian
hormones to provide a microenvironment rich in cell
adhesion molecules, cytokines, chemokines and growth
factors [1,4,49,50].
Activins have been described as important regulators
of decidualisation and endometrial receptivity following
the identification of their expression in the endometrium
of several species at the gene and protein levels. Activin
subunits are expressed in the endometrium luminal and
glandular epithelium of several species including human
[21,34,51,52]. The co-expression of activin subunits, re-
ceptors and binding protein indicates that endometrial
epithelial and stromal cells are capable of generating and
responding to activin, and that there is a tight local regu-
lation of activin actions within the endometrium [53].
The expression of activin and its related molecules
varies during the menstrual cycle in the human endo-
metrium as the uterus remodels and differentiates to
form the decidua [54,55]. Activin βA- and βB-subunits
mRNA and protein are expressed by glandular and
surface epithelium in non-pregnant endometrium [55]
and, dimeric activin-A is present in uterine fluid [53]
and menstrual blood [56] of cycling women. The expres-
sion of activin subunits is localised in the cytoplasm of
endometrial epithelium and it significantly increases in
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secretory phase and remains relatively constant over the
rest of the cycle [53,55]. Furthermore, activin-A measured
in endometrial washes collected from cycling women
correlated significantly with menstrual cycle days and the
thickness of endometrium [53].
A similar pattern of expression has also been observed
in the stromal cells during the cycle and the expression
was strongest in the late secretory phase where decidua-
lisation and embryo implantation occur [54,55]. Further
evidence for the up-regulation of activin subunits syn-
thesis with decidualisation was obtained from studies
where the endometrium was extensively decidualised by
intrauterine delivery of progestin [57] and in gene array
studies examining decidualisation-related genes [58]. Newly
decidualised cells are the main source of maternally derived
activin-A during pregnancy to facilitate the spread of decid-
ualisation throughout the endometrium by promoting the
decidualisation of neighbouring cells [32-34,57,59].
During pregnancy, the placenta is a major source of
serum activin-A, which increases as the pregnancy pro-
gresses [21,24,60,61]. However, the expression of activins
by the cytotrophoblast is low during early pregnancy
suggesting that trophoblast invasion is induced by mater-
nally derived activins [32]. Activin-A regulates trophoblastic
cell adhesive properties by modulating the expression of
E- and N-cadherin [62,63] and integrins [35]. activin-A
also promotes invasion of first-trimester cytotrophoblasts
until 10 weeks gestation by increasing the expression of
matrix metalloproteinases-2, 7 and 9 and its actions are
inhibited by follistatin [33].Table 1 Characteristics of published studies that investigated












Florio et al. 2007 Prospective
Observational
536 PUL Not re
Kirk et al. 2009 Prospective
Observational
141 PUL Not re
Florio et al. 2011 Retrospective
case–control
30 EP & 30 IUP Between 6
Rausch et al. 2011 Retrospective
case–control
100 EP & 100 IUP EP 45.15
IUP 48.8 ±
Warrick et al. 2012 Retrospective
cohort study
89 EP, 100





Roghaei et al. 2012 Prospective
case–control
100 EP & 100 IUP EP 6.32 ±
IUP 6.85 ±
Daponte et al. 2013 Prospective
case–control
30 EP,
30 AB & 33 IUP
Between 6
(AUC = area under the curve by receiver operator characteristics).Activins in the pathogenesis and diagnosis of EP
Studies on the expression pattern of activins, their type
II receptors and follistatin by fallopian tubes bearing an
ectopic pregnancy have shown a significant increase in
βA-subunit, type IIA and IIB receptors and follistatin
compared to normal control [6,10]. Coherently, an in-
crease in the expression of those molecules was also ob-
served in tubal samples collected from patients with EP
and who were positive for Chlamydia trachomatis anti-
bodies when compared to tubal samples collected from
EP patients and who had negative reaction for the anti-
bodies [5]. Nevertheless, a recent study did not detect
significant difference in the expression pattern of these
molecules between implantation and remote sites col-
lected from archived tubal pregnancy specimens. Hence, it
has been postulated that the pathologic expression of acti-
vins and their related molecules by the tubal epithelium
may play an important role in the pathogenesis of EP but
not in the determination of implantation site [10].
Serum levels of activin-A and follistatin increase sig-
nificantly throughout pregnancy and several studies have
proposed a feto-placental origin for these proteins. Serum
levels of activin-A also decrease in the presence of non-
viable trophoblast [21,64,65]. Consequently, activin-A
has been investigated as a potential marker for the diag-
nosis and differentiation between normal intrauterine
pregnancy (IUP), miscarriage and ectopic pregnancy
[37]. However, the reported results about the diagnostic
value of activin-A are still debatable (Table 1).
The initial study by Florio et al. (2007) [36] demon-
strated that a single measurement of serum activin-Athe diagnostic value of a single measurement of serum





AUC Sensitivity Specificity Reference
number
ported 370 pg/mL 1.00 100% 99.6% [36]
ported 370 pg/mL 0.51 93% 13% [71]
to 8 weeks 430 pg/mL 0.99 96.7% 100% [66]
± 18.95;
18.34 days





< 260 pg/mL 0.62 59.6% 61% [72]
1.03 weeks;
1.82 weeks
504 pg/mL 0.981 97% 93.5% [69]
to 8 weeks 504 pg/mL 0.979 87.9% 100% [67]
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patients with pregnancy of unknown location (PUL) to
discriminate between viable normal IUP, miscarriage and
EP with a sensitivity of 100% and specificity of 99.6% at
a cut-off value of 370 pg/mL. Later, the same research
team has reported that serum concentrations of activin-
A were significantly lower in 30 patients diagnosed with
tubal EP when compared to control and, a sensitivity of
96.7% and a specificity of 100% for the diagnosis of EP
was achieved at the cut-off level of 0.43 ng/mL [66].
These results have also been confirmed by other re-
search groups in the following years but with a different
cut-off value of 504 pg/mL that achieved a sensitivity of
97% and specificity of 93.5% [22,67-70]. Additionally,
Daponte et al. (2013) [67] also measured the sensitivity
and specificity of follistatin in the diagnosis of EP. Their
results have shown that both serum follistatin and
activin-A/follistatin ratio had lower performance com-
pared to serum activin-A in the diagnosis of EP.
Oppositely, another two studies reported that a single
measurement of serum activin-A was neither sensitive
nor specific for the diagnosis of early pregnancy failure
including EP compared to β-hCG [71,72]. Their results
demonstrated that serum activin-A levels gave an area
under the curve (AUC) of 0.61 for failing PUL, 0.64 for
IUP and 0.51 for EP, and the model based on serum
hCG levels gave an AUC of 0.95 for failing PUL, 0.97 for
IUP and 0.67 for EP [71].
The inconsistencies in the reported cut-off values and
the results of the different studies could be due to vari-
ability in trophoblastic activities and inadequate decidu-
lisation during ectopic implantation [67]. It has also
been suggested that some trophoblastic cells may behave
as failing pregnancy during EP while other EPs could
have more activity and behave more like IUPs [71],
which could provide a possible explanation for the re-
ported variations in serum levels of activin-A in women
with EP [67].
Another explanation for the aforementioned variations
in the results of activin-A could be related to the gesta-
tional age of the enrolled participants in the different stud-
ies. The increase in serum activin-A and follistatin during
normal pregnancy starts at week 6 and reaches its peak at
week 38 of pregnancy. The original study by Florio et al.
(2007) [36]. included patients in the first trimester but the
authors have not reported the gestational age for control,
EP and miscarriage groups. In the following study by
Rausch et al. (2011), the mean gestational age for EP and
IUP was 45.15 ± 18.95 and 48.8 ± 18.34 days, respectively
[22]. The most recent studies that have reported a diag-
nostic value for serum activin-A included only patients
between 6 to 8 [67] and 5 to 6 weeks gestational age [70].
Alternatively, the two studies that showed no value for
serum activin-A in the diagnosis of EP the gestationalage for each group was not reported by Kirk et al. (2009)
[71] and Warrick et al. (2012) [72] applied a retrospective
design that included pregnant females with ≤10 weeks ges-
tation. The ectopic pregnancy group in study reported by
Warrick et al. (2012) [72] had a median of 5 weeks (range
1–10 weeks) gestation compared to 7 weeks (range 1–10
weeks) for both IUP and miscarriage. Therefore, future
studies should categorise the patients with failing early
pregnancy according to gestational age (e.g. ≤ and >6 weeks)
and to compare the results with those obtained from gesta-
tional aged matched controls.
The biological activities of activins are tightly regulated
by follistatin as the binding of activin to follistatin is al-
most irreversible [23]. Serum activin is commonly bound
with the long form follistatin (FS-315) [29], while the
short form (FS-288) has high affinity for cell membrane
activins [73]. The currently available ELISA kits for the
detection of activin-A and follistatin cannot distinguish
between the free and bound forms of both proteins. Fur-
thermore, the follistatin kit measures both the long and
short forms. Therefore, the reported results from the dif-
ferent studies are shown at the level of total activin-A
and follistatin and the development of ELISA kits that
measure the free form of both proteins would expose
precisely their values in the diagnosis of early pregnancy
failure.
Additionally, the majority of studies that demonstrated
the localisation of activins in the endometrium and pla-
cental tissues investigated the expression pattern of the
βA- and βB-subunits and not the mature dimeric proteins.
Hence, it could be postulated that the endometrium and
trophoblast are cable of synthesising the different activin
mature dimers (activin-A, −B and -AB). Moreover, gener-
ated results from gene knock-out studies have shown that
each activin subunit has distinct functions and these sub-
units do not functionally overlap in all settings in vivo
[74,75]. Hence, the inclusion of the other activin mature
dimeric proteins (e.g. activin-B and –AB) could add to the
performance of serum activin-A in the diagnosis of abnor-
mal early pregnancy.
Conclusions
Ectopic pregnancy is worldwide health problem and it is
the leading cause of maternal morbidity and/or mortality
during the first trimester. Early diagnosis of EP would
allow more conservative treatment approaches and pres-
ervation of prospective fertility. However, the currently
used diagnostic modalities lack accuracy, reproducibility
and simplicity in the prediction of EP.
Activins and their related proteins play an important
role in the regulation of endometrial receptivity, tropho-
blast activity and embryo implantation. Pathological ex-
pression of these candidate proteins have been associated
with abnormal implantation and failing early pregnancy at
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of a single measurement of serum activin-A in differenti-
ating abnormal from normal pregnancy is controversial, it
merits further research.
Future studies should classify the patients according to
the gestational age and to include other activin mature
dimer proteins. It could also be worthy to combine serum
activins with other serum biomarkers (e.g. inhibins, vascu-
lar endothelial growth factor) for early and accurate diag-
nosis of EP. Additionally, the development of ELISA kits
that measure the free form of activins could increase their
diagnostic performances. Further studies are needed to
develop biomarkers and diagnostic modalities for the early
diagnosis of EP and prevention of its associated maternal
complications.
Competing interests
The author declares that he has no competing interests.
Acknowledgements
The author would like to thank the Institute of Scientific Research and Revival of
Islamic Heritage at Umm Al-Qura University (project # 43309009) for the financial
support.
Received: 20 September 2014 Accepted: 17 November 2014
Published: 25 November 2014
References
1. Singh M, Chaudhry P, Asselin E: Bridging endometrial receptivity and
implantation: network of hormones, cytokines, and growth factors.
J Endocrinol 2011, 210:5–14.
2. Dimitriadis E, White CA, Jones RL, Salamonsen LA: Cytokines, chemokines
and growth factors in endometrium related to implantation. Hum Reprod
Update 2005, 11:613–630.
3. Coughlan C, Ledger W, Wang Q, Liu F, Demirol A, Gurgan T, Cutting R, Ong
K, Sallam H, Li TC: Recurrent implantation failure: definition and
management. Reprod Biomed Online 2014, 28:14–38.
4. Jia-Rong Z, Shuang-Di L, Xiao-Ping W: Eutopic or ectopic pregnancy: a
competition between signals derived from the endometrium and the
fallopian tube for blastocyst implantation. Placenta 2009, 30:835–839.
5. Refaat B, Al-Azemi M, Geary I, Eley A, Ledger W: Role of activins and inducible
nitric oxide in the pathogenesis of ectopic pregnancy in patients with or
without Chlamydia trachomatis infection. Clin Vaccine Immunol 2009,
16:1493–1503.
6. Refaat B, Amer S, Ola B, Chapman N, Ledger W: The expression of activin-
betaA- and -betaB-subunits, follistatin, and activin type II receptors in
fallopian tubes bearing an ectopic pregnancy. J Clin Endocrinol Metab
2008, 93:293–299.
7. Jurkovic D, Wilkinson H: Diagnosis and management of ectopic pregnancy.
BMJ 2011, 342:d3397.
8. Sivalingam VN, Duncan WC, Kirk E, Shephard LA, Horne AW: Diagnosis and
management of ectopic pregnancy. J Fam Plann Reprod Health Care 2011,
37:231–240.
9. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF: WHO analysis
of causes of maternal death: a systematic review. Lancet 2006,
367:1066–1074.
10. Refaat B, Simpson H, Britton E, Biswas J, Wells M, Aplin JD, Ledger W: Why
does the fallopian tube fail in ectopic pregnancy? The role of activins,
inducible nitric oxide synthase, and MUC1 in ectopic implantation. Fertil
Steril 2012, 97:1115–1123.
11. Kao LY, Scheinfeld MH, Chernyak V, Rozenblit AM, Oh S, Dym RJ: Beyond
ultrasound: CT and MRI of ectopic pregnancy. AJR Am J Roentgenol 2014,
202:904–911.
12. Kirk E, Bottomley C, Bourne T: Diagnosing ectopic pregnancy and current
concepts in the management of pregnancy of unknown location. Hum
Reprod Update 2014, 20:250–261.13. Hajenius PJ, Mol F, Mol BW, Bossuyt PM, Ankum WM, van der Veen F:
Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev
2007, 1:CD000324.
14. Lipscomb GH: Medical therapy for ectopic pregnancy. Semin Reprod Med
2007, 25:93–98.
15. Bachman EA, Barnhart K: Medical management of ectopic pregnancy: a
comparison of regimens. Clin Obstet Gynecol 2012, 55:440–447.
16. Dillon KE, Sioulas VD, Sammel MD, Chung K, Takacs P, Shaunik A, Barnhart
KT: How and when human chorionic gonadotropin curves in women
with an ectopic pregnancy mimic other outcomes: differences by race
and ethnicity. Fertil Steril 2012, 98:911–916.
17. Morse CB, Sammel MD, Shaunik A, Allen-Taylor L, Oberfoell NL, Takacs P,
Chung K, Barnhart KT: Performance of human chorionic gonadotropin
curves in women at risk for ectopic pregnancy: exceptions to the rules.
Fertil Steril 2012, 97:101–106. e2.
18. Cartwright J, Duncan WC, Critchley HO, Horne AW: Serum biomarkers of
tubal ectopic pregnancy: current candidates and future possibilities.
Reproduction 2009, 138:9–22.
19. Cabar FR, Fettback PB, Pereira PP, Zugaib M: Serum markers in the
diagnosis of tubal pregnancy. Clinics (Sao Paulo) 2008, 63:701–708.
20. Barnhart K, Speicher DW: Molecular diagnosis of ectopic pregnancy. Expert
Rev Mol Diagn 2011, 11:759–762.
21. Florio P, Luisi S, Ciarmela P, Severi FM, Bocchi C, Petraglia F: Inhibins and
activins in pregnancy. Mol Cell Endocrinol 2004, 225:93–100.
22. Rausch ME, Sammel MD, Takacs P, Chung K, Shaunik A, Barnhart KT:
Development of a multiple marker test for ectopic pregnancy. Obstet
Gynecol 2011, 117:573–582.
23. Refaat BA, Bahathiq AO, Sockanathan S, Stewart RL, Wells M, Ledger WL:
Production and localization of activins and activin type IIA and IIB
receptors by the human endosalpinx. Reproduction 2004, 128:249–255.
24. Schneider-Kolsky M, D’Antona D, Evans LW, Taylor N, O’Connor A, Groome
NP, de Kretser D, Wallace EM: Maternal serum total activin A and
follistatin in pregnancy and parturition. BJOG 2000, 107:995–1000.
25. Barton DE, Yang-Feng TL, Mason AJ, Seeburg PH, Francke U: Mapping of
genes for inhibin subunits alpha, beta A, and beta B on human and
mouse chromosomes and studies of jsd mice. Genomics 1989, 5:91–99.
26. Mason AJ, Hayflick JS, Ling N, Esch F, Ueno N, Ying SY, Guillemin R, Niall H,
Seeburg PH: Complementary DNA sequences of ovarian follicular fluid
inhibin show precursor structure and homology with transforming
growth factor-beta. Nature 1985, 318:659–663.
27. Ebner R, Chen RH, Lawler S, Zioncheck T, Derynck R: Determination of type
I receptor specificity by the type II receptors for TGF-beta or activin.
Science 1993, 262:900–902.
28. Wrana JL, Tran H, Attisano L, Arora K, Childs SR, Massague J, O’Connor MB:
Two distinct transmembrane serine/threonine kinases from Drosophila
melanogaster form an activin receptor complex. Mol Cell Biol 1994,
14:944–950.
29. Schneyer AL, Hall HA, Lambert-Messerlian G, Wang QF, Sluss P, Crowley
WF Jr: Follistatin-activin complexes in human serum and follicular
fluid differ immunologically and biochemically. Endocrinology 1996,
137:240–247.
30. Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS: The structure
of the follistatin:activin complex reveals antagonism of both type I and
type II receptor binding. Dev Cell 2005, 9:535–543.
31. Bahathiq AO, Stewart RL, Wells M, Moore HD, Pacey AA, Ledger WL:
Production of activins by the human endosalpinx. J Clin Endocrinol Metab
2002, 87:5283–5289.
32. Jones RL, Findlay JK, Farnworth PG, Robertson DM, Wallace E, Salamonsen
LA: Activin A and inhibin A differentially regulate human uterine matrix
metalloproteinases: potential interactions during decidualization and
trophoblast invasion. Endocrinology 2006, 147:724–732.
33. Jones RL, Findlay JK, Salamonsen LA: The role of activins during decidualisation
of human endometrium. Aust N Z J Obstet Gynaecol 2006, 46:245–249.
34. Jones RL, Kaitu’u-Lino TJ, Nie G, Sanchez-Partida LG, Findlay JK, Salamonsen
LA: Complex expression patterns support potential roles for maternally
derived activins in the establishment of pregnancy in mouse.
Reproduction 2006, 132:799–810.
35. Stoikos CJ, Salamonsen LA, Hannan NJ, O’Connor AE, Rombauts L,
Dimitriadis E: Activin A regulates trophoblast cell adhesive properties:
implications for implantation failure in women with endometriosis-
associated infertility. Hum Reprod 2010, 25:1767–1774.
Refaat Reproductive Biology and Endocrinology 2014, 12:116 Page 8 of 8
http://www.rbej.com/content/12/1/11636. Florio P, Severi FM, Bocchi C, Luisi S, Mazzini M, Danero S, Torricelli M,
Petraglia F: Single serum activin a testing to predict ectopic pregnancy.
J Clin Endocrinol Metab 2007, 92:1748–1753.
37. Prakash A, Laird S, Tuckerman E, Li TC, Ledger WL: Inhibin A and activin A
may be used to predict pregnancy outcome in women with recurrent
miscarriage. Fertil Steril 2005, 83:1758–1763.
38. Refaat B, Ledger W: The expression of activins, their type II receptors and
follistatin in human Fallopian tube during the menstrual cycle and in
pseudo-pregnancy. Hum Reprod 2011, 26:3346–3354.
39. Lyons RA, Saridogan E, Djahanbakhch O: The effect of ovarian follicular
fluid and peritoneal fluid on Fallopian tube ciliary beat frequency. Hum
Reprod 2006, 21:52–56.
40. Kriebs JM, Fahey JO: Ectopic pregnancy. J Midwifery Womens Health 2006,
51:431–439.
41. Lu RZ, Matsuyama S, Nishihara M, Takahashi M: Developmental expression
of activin/inhibin beta A, beta B, and alpha subunits, and activin
receptor-IIB genes in preimplantation mouse embryos. Biol Reprod 1993,
49:1163–1169.
42. Gandolfi F, Modina S, Brevini TA, Passoni L, Artini P, Petraglia F, Lauria A:
Activin beta A subunit is expressed in bovine oviduct. Mol Reprod Dev
1995, 40:286–291.
43. Sidis Y, Fujiwara T, Leykin L, Isaacson K, Toth T, Schneyer AL:
Characterization of inhibin/activin subunit, activin receptor, and
follistatin messenger ribonucleic acid in human and mouse oocytes:
evidence for activin’s paracrine signaling from granulosa cells to
oocytes. Biol Reprod 1998, 59:807–812.
44. He ZY, Liu HC, Mele CA, Barmat L, Veeck LL, Davis O, Rosenwaks Z:
Expression of inhibin/activin subunits and their receptors and binding
proteins in human preimplantation embryos. J Assist Reprod Genet 1999,
16:73–80.
45. Nusing RM, Barsig J: Inflammatory potency of activin A. Effect on prostanoid
and nitric oxide formation. Adv Exp Med Biol 1997, 407:243–248.
46. Lagadec P, Raynal S, Lieubeau B, Onier N, Arnould L, Saint-Giorgio V,
Lawrence DA, Jeannin JF: Evidence for control of nitric oxide synthesis by
intracellular transforming growth factor-beta1 in tumor cells. Implications
for tumor development. Am J Pathol 1999, 154:1867–1876.
47. Nusing RM, Barsig J: Induction of prostanoid, nitric oxide, and cytokine
formation in rat bone marrow derived macrophages by activin A.
Br J Pharmacol 1999, 127:919–926.
48. Ciarmela P, Wiater E, Vale W: Activin-A in myometrium: characterization of
the actions on myometrial cells. Endocrinology 2008, 149:2506–2516.
49. Horne AW, Critchley HO: Mechanisms of disease: the endocrinology of
ectopic pregnancy. Expert Rev Mol Med 2012, 14:e7.
50. Shaw JL, Horne AW: The paracrinology of tubal ectopic pregnancy.
Mol Cell Endocrinol 2012, 358:216–222.
51. Sugawara K, Kizaki K, Herath CB, Hasegawa Y, Hashizume K: Transforming
growth factor beta family expression at the bovine feto-maternal interface.
Reprod Biol Endocrinol 2010, 8:120.
52. Zhang H, Nagaoka K, Imakawa K, Nambo Y, Watanabe G, Taya K, Weng Q:
Expression of inhibin/activin subunits in the equine uteri during the
early pregnancy. Reprod Domest Anim 2013, 48:423–428.
53. Florio P, Severi FM, Luisi S, Ciarmela P, Calonaci G, Cobellis L, Petraglia F:
Endometrial expression and secretion of activin A, but not follistatin,
increase in the secretory phase of the menstrual cycle. J Soc Gynecol
Investig 2003, 10:237–243.
54. Mylonas I, Makovitzky J, Hoeing A, Richter DU, Vogl J, Schulze S, Jeschke U,
Briese V, Friese K: Inhibin/activin subunits beta-A (−betaA) and beta-B
(−betaB) are differentially localised in normal, hyperplastic and malignant
human endometrial tissue. Acta Histochem 2006, 108:1–11.
55. Mylonas I, Jeschke U, Wiest I, Hoeing A, Vogl J, Shabani N, Kuhn C, Schulze
S, Kupka MS, Friese K: Inhibin/activin subunits alpha, beta-A and beta-B
are differentially expressed in normal human endometrium throughout
the menstrual cycle. Histochem Cell Biol 2004, 122:461–471.
56. Reis FM, Nascimento LL, Tsigkou A, Ferreira MC, Luisi S, Petraglia F: Activin
A and follistatin in menstrual blood: low concentrations in women with
dysfunctional uterine bleeding. Reprod Sci 2007, 14:383–389.
57. Jones RL, Salamonsen LA, Zhao YC, Ethier JF, Drummond AE, Findlay JK:
Expression of activin receptors, follistatin and betaglycan by human
endometrial stromal cells; consistent with a role for activins during
decidualization. Mol Hum Reprod 2002, 8:363–374.58. Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, Osteen K, Taylor RN,
Lessey BA, Giudice LC: Global gene profiling in human endometrium
during the window of implantation. Endocrinology 2002, 143:2119–2138.
59. Jones RL, Salamonsen LA, Findlay JK: Activin A promotes human
endometrial stromal cell decidualization in vitro. J Clin Endocrinol Metab
2002, 87:4001–4004.
60. Fowler PA, Evans LW, Groome NP, Templeton A, Knight PG: A longitudinal study
of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-alphaC and
follistatin during pregnancy. Hum Reprod 1998, 13:3530–3536.
61. O’Connor AE, McFarlane JR, Hayward S, Yohkaichiya T, Groome NP, de
Kretser DM: Serum activin A and follistatin concentrations during human
pregnancy: a cross-sectional and longitudinal study. Hum Reprod 1999,
14:827–832.
62. Ferreira MC, Witz CA, Hammes LS, Kirma N, Petraglia F, Schenken RS, Reis
FM: Activin A increases invasiveness of endometrial cells in an in vitro
model of human peritoneum. Mol Hum Reprod 2008, 14:301–307.
63. Li Y, Klausen C, Cheng JC, Zhu H, Leung PC: Activin A, B and AB increase
human trophoblast cell invasion by up-regulating N-cadherin. J Clin
Endocrinol Metab 2014, 99:jc20142118.
64. Luisi S, Florio P, D’Antona D, Severi FM, Sanseverino F, Danero S, Petraglia F:
Maternal serum inhibin A levels are a marker of a viable trophoblast in
incomplete and complete miscarriage. Eur J Endocrinol 2003, 148:233–236.
65. Muttukrishna S, Jauniaux E, Greenwold N, McGarrigle H, Jivraj S, Carter S,
Elgaddal S, Groome N, Regan L: Circulating levels of inhibin A, activin A
and follistatin in missed and recurrent miscarriages. Hum Reprod 2002,
17:3072–3078.
66. Florio P, Reis FM, Battista R, Luisi S, Moncini I, Bocchi C, Severi FM, Petraglia F:
Serum activin A levels are lower in tubal than intrauterine spontaneously
conceived pregnancies. Gynecol Endocrinol 2011, 27:391–395.
67. Daponte A, Deligeoroglou E, Garas A, Pournaras S, Hadjichristodoulou C,
Messinis IE: Activin A and follistatin as biomarkers for ectopic pregnancy
and missed abortion. Dis Markers 2013, 35:497–503.
68. Rausch ME, Barnhart KT: Serum biomarkers for detecting ectopic
pregnancy. Clin Obstet Gynecol 2012, 55:418–423.
69. Roghaei MA, Sabet F, Mohamadi K: Diagnostic accuracy of serum activin A
in detection of ectopic pregnancy. J Res Med Sci 2012, 17:378–381.
70. Elito Junior J, Gustavo Oliveira L, Octavio Fernandes Silva M, Araujo Junior E,
Camano L: Serum activin A levels and tubal ectopic pregnancy. Iran J
Reprod Med 2014, 12:227–228.
71. Kirk E, Papageorghiou AT, Van Calster B, Condous G, Cowans N, Van Huffel
S, Timmerman D, Spencer K, Bourne T: The use of serum inhibin A and
activin A levels in predicting the outcome of ‘pregnancies of unknown
location’. Hum Reprod 2009, 24:2451–2456.
72. Warrick J, Gronowski A, Moffett C, Zhao Q, Bishop E, Woodworth A: Serum
activin A does not predict ectopic pregnancy as a single measurement
test, alone or as part of a multi-marker panel including progesterone
and hCG. Clin Chim Acta 2012, 413:707–711.
73. Nakamura T, Sugino K, Titani K, Sugino H: Follistatin, an activin-binding
protein, associates with heparan sulfate chains of proteoglycans on
follicular granulosa cells. J Biol Chem 1991, 266:19432–19437.
74. Brown CW, Houston-Hawkins DE, Woodruff TK, Matzuk MM: Insertion of
Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals
new activin functions. Nat Genet 2000, 25:453–457.
75. Brown CW, Li L, Houston-Hawkins DE, Matzuk MM: Activins are critical
modulators of growth and survival. Mol Endocrinol 2003, 17:2404–2417.
doi:10.1186/1477-7827-12-116
Cite this article as: Refaat: Role of activins in embryo implantation and
diagnosis of ectopic pregnancy: a review. Reproductive Biology and
Endocrinology 2014 12:116.
